for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Sichuan Kelun Pharmaceutical Co Ltd

002422.SZ

Latest Trade

22.91CNY

Change

-0.23(-0.99%)

Volume

23,930,445

Today's Range

22.79

 - 

23.65

52 Week Range

18.89

 - 

33.50

As of on the Shenzhen Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
23.14
Open
23.14
Volume
23,930,445
3M AVG Volume
309.45
Today's High
23.65
Today's Low
22.79
52 Week High
33.50
52 Week Low
18.89
Shares Out (MIL)
1,439.79
Market Cap (MIL)
32,351.99
Forward P/E
25.58
Dividend (Yield %)
1.89

Latest Developments

More

Sichuan Kelun Pharmaceutical's Prelim 2019 Net Profit Down 22.9 Y/Y

Sichuan Kelun Pharmaceutical To Sell Stake In Unit For 512 Mln Yuan

Sichuan Kelun Pharmaceutical Plans Share Buyback Of Up To 200 Mln Yuan

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Sichuan Kelun Pharmaceutical Co Ltd

SICHUAN KELUN PHARMACEUTICAL CO., LTD. is a China-based company, principally engaged in the research and development, manufacture and distribution of pharmaceutical products. The Company operates its businesses through manufacture and distribution of injections, booster injections, lyophilized power injections, tablets, capsules, granules, oral liquids, dialysis fluids and other form of pharmaceuticals, bulk pharmaceutical chemicals, pharmaceutical packing materials, as well as medical equipment. The Company's injection products include general injections and therapeutic injections, such as glucose injections, sodium chloride injections, glucose and sodium chloride injections, ofloxacin injections, metronidazole injections and norfloxacin injections, among others. Through its subsidiaries, it also engages in the manufacture of rubber and plastic products. The Company distributes its products within domestic market and to overseas markets.

Industry

Biotechnology & Drugs

Contact Info

No.36

Baihua West Road, Qingyang District

CHENGDU, SIC

610071

China

+86.28.82860516

http://www.kelun.com

Executive Leadership

Gexin Liu

Chairman of the Board

Degui Lai

Chief Financial Officer, Deputy General Manager

Sichuan Liu

General Manager, Director

Hao Feng

Deputy General Manager, Secretary of the Board

Jingyi Wang

Deputy General Manager, Director

Key Stats

1.78 mean rating - 9 analysts
Sell
Hold
Buy
Revenue (MM, CNY)

2017

11.4K

2018

16.4K

2019

17.6K

2020(E)

18.8K
EPS (CNY)

2017

0.520

2018

0.850

2019

0.660

2020(E)

0.833
Price To Earnings (TTM)
51.84
Price To Sales (TTM)
1.92
Price To Book (MRQ)
2.46
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
87.90
LT Debt To Equity (MRQ)
26.92
Return on Investment (TTM)
3.93
Return on Equity (TTM)
2.21

Latest News

Latest News

BRIEF-Sichuan Kelun Pharmaceutical's Prelim 2019 Net Profit Down 22.9 Y/Y

* SAYS PRELIM 2019 NET PROFIT DOWN 22.9% Y/Y AT 935.4 MILLION YUAN ($133.38 million)

BRIEF-Sichuan Kelun Pharmaceutical sees 2018 H1 net profit to up 180 pct to 230 pct

* Says net profit for 2018 H1 to up 180 percent to 230 percent

BRIEF-Sichuan Kelun Pharmaceutical to pay cash dividend of 2.09 yuan per 10 shares (before tax) for 2017

* Says it plans to pay cash dividend of 2.09 yuan per 10 shares (before tax) to shareholders for 2017

BRIEF-Sichuan Kelun Pharmaceutical's Net Profits Up In 2017, Q1

* SAYS Q1 NET PROFIT UP 98.91 PERCENT Y/Y Source text in Chinese: https://bit.ly/2HoGRGp; https://bit.ly/2HKLL05 Further company coverage: (Reporting by Hong Kong newsroom)

BRIEF-Sichuan Kelun Pharmaceutical issues 2018 4th tranche super short-term financing notes worth 400 mln yuan

* Says it completed issuance of 2018 4th tranche super short-term financing notes worth 400 million yuan

BRIEF-Sichuan Kelun Pharmaceutical issues 2018 1st tranche corporate bonds worth 400 mln yuan

* Says it completed issuance of 2018 1st tranche public corporate bonds worth 400 million yuan

BRIEF-Sichuan Kelun Pharmaceutical Sees Q1 Net Profit Up 80-120 Percent Y/Y

* SAYS IT SEES Q1 NET PROFIT UP 80-120 PERCENT Y/Y FROM 192.6 MILLION YUAN ($30.65 million) YEAR AGO Source text in Chinese: https://bit.ly/2utt1wC Further company coverage: ($1 = 6.2848 Chinese yuan renminbi) (Reporting by Hong Kong newsroom)

BRIEF-Sichuan Kelun Pharmaceutical sets coupon rate for 2018 first tranche corporate bonds at 5.84 pct

* Says it will issue 2018 first tranche corporate bonds worth 400 million yuan, with coupon rate of 5.84 percent

BRIEF-Shenzhen Exchange Filing Shows Block Trade Of Sichuan Kelun Pharmaceutical Involving 200 Mln Yuan

* FILING SHOWS BLOCK TRADE OF SICHUAN KELUN PHARMACEUTICAL CO LTD'S 7.6 MILLION SHARES INVOLVING 200 MILLION YUAN ($31.64 million) ON MARCH 23 Source text in Chinese: https://bit.ly/2grA0v1 Further company coverage: ($1 = 6.3210 Chinese yuan renminbi) (Reporting by Hong...

BRIEF-Sichuan Kelun Pharmaceutical unit receives approval for drug clinical trial

* Says its Sichuan-based biomedicine unit received approval for drug clinical trial for a kind of injection, from China Food and Drug Administration

BRIEF-Sichuan Kelun Pharmaceutical issues 2018 3rd tranche super short-term financing notes worth 600 mln yuan

* Says it completed issuance of 2018 3rd tranche super short-term financing notes worth 600 million yuan, at coupon rate of 5.50 percent

BRIEF-Sichuan Kelun Pharmaceutical issues 2018 second tranche super short-term financing notes worth 700 mln yuan

* Says it issued 2018 second tranche super short-term financing notes worth 700 million yuan with a term of 270 days and coupon rate of 5.65 percent

BRIEF-Sichuan Kelun Pharmaceutical sees FY 2017 net profit to up 15 pct to 45 pct

* Sees FY 2017 net profit to increase by 15 percent to 45 percent, or to be 672.3 million yuan to 847.7 million yuan

BRIEF-Sichuan Kelun Pharmaceutical issues 2018 first tranche mid-term bills worth 500 mln yuan

* Says it issued 2018 first tranche mid-term bills worth 500 million yuan, with a term of three years and an interest of 6.2 percent

BRIEF-Sichuan Kelun Pharmaceutical unit receives approval for construction of engineering technology center

* Says co's biotechnology unit received approval from Ministry of Environmental Protection of the People's Republic of China, for construction of environmental protection antibiotic residue harmless treatment and resource utilization related engineering technology center

BRIEF-Sichuan Kelun Pharmaceutical issues 2018 1st tranche super short-term financing notes worth 800 mln yuan

* Says it completed issuance of 2018 1st tranche super short-term financing notes worth 800 million yuan

BRIEF-Sichuan Kelun Pharmaceutical to acquire 90 pct stake in biomedicine firm for 19.7 mln yuan

* Says it signs agreement to acquire 90 percent stake in a Xinjiang-based biomedicine firm, at the price of 19.7 million yuan

BRIEF-Sichuan Kelun Pharmaceutical buys back 33.3 mln yuan worth of company shares

* Says it buys back 33.3 million yuan worth of company shares (0.15 percent stake) until Nov. 30

BRIEF-Sichuan Kelun Pharmaceutical issues 2017 sixth tranche super short-term financing notes worth 500 mln yuan

* Says it issued 2017 sixth tranche super short-term financing notes worth 500 million yuan, with coupon rate of 4.98 percent and a term of 270 days

BRIEF-Sichuan Kelun Pharmaceutical unit gets approval for drug clinic trial

* Says its unit received clinic trial approval for muscle injection from China Food and Drug Administration

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up